All Posts
WHO: 10 key global health moments from 2021.
8 Jan, 2022 | 23:20h | UTC10 key global health moments from 2021 – World Health Organization
Commentary on Twitter (thread – click for more)
10 key global health moments from 2021 https://t.co/QYt8jV9WWh pic.twitter.com/ZPoM3zFPzI
— World Health Organization (WHO) (@WHO) December 21, 2021
AHA Scientific Statement | Hypertension in pregnancy: diagnosis, blood pressure goals, and pharmacotherapy.
8 Jan, 2022 | 23:16h | UTCNews Release: High blood pressure treatment in pregnancy is safe, prevents maternal heart risks – American Heart Association
Commentary on Twitter
Have you had a chance to check out the new Scientific Statement From the American Heart Association?!?
Hypertension in Pregnancy: Diagnosis, Blood Pressure Goals, and Pharmacotherapy: A Scientific Statement From the American Heart Associationhttps://t.co/hs6zPwOP2N pic.twitter.com/CUs1jxCP5M
— Hypertension (@HyperAHA) December 20, 2021
AAN Guideline: Oral and topical treatment of painful diabetic polyneuropathy.
8 Jan, 2022 | 23:18h | UTCNews Release: AAN Issues Guideline for Treatment of Painful Diabetic Neuropathy – American Academy of Neurology
AHA names top heart disease and stroke research advances of 2021.
8 Jan, 2022 | 23:14h | UTCAHA names top heart disease and stroke research advances of 2021 – American Heart Association
New AAP Guidance recommends routine HIV screening to all youth 15 years or older.
8 Jan, 2022 | 23:13h | UTCCommentary: Pediatricians Can Play Key Role in HIV Testing, Prophylaxis – HealthDay
RCT: In older patients undergoing hip fracture surgery, regional anesthesia did not reduce the incidence of postoperative delirium compared to general anesthesia.
8 Jan, 2022 | 23:09h | UTCEffect of Regional vs General Anesthesia on Incidence of Postoperative Delirium in Older Patients Undergoing Hip Fracture Surgery: The RAGA Randomized Trial – JAMA (link to abstract – $ for full-text)
Commentary: China-wide study will boost understanding of fatal surgical complication – University of Birmingham
Related:
RCT: Spinal Anesthesia not Superior to General Anesthesia for Hip Surgery in Older Adults.
FDA approves first injectable treatment for HIV pre-exposure prevention.
8 Jan, 2022 | 23:04h | UTCCommentaries:
NIH celebrates FDA approval of long-acting injectable drug for HIV prevention – NIH News Releases
A new injection to prevent HIV, rather than pills, is a game-changer, scientists say – NPR
Related:
CDC Guidance: Preexposure Prophylaxis for Prevention of HIV Acquisition Among Adolescents
USPSTF Statement: Preexposure Prophylaxis for the Prevention of HIV Infection
British Guidelines on the Use of HIV Pre–exposure Prophylaxis (PrEP) (several guidelines on the subject)
New Protocol for HIV Prevention Drug Reduces The Number Of Pills Required
RCT: Long-term supplementation with marine Omega-3 fatty acids does not reduce the risk of depressive symptoms.
8 Jan, 2022 | 23:10h | UTCEffect of Long-term Supplementation With Marine Omega-3 Fatty Acids vs Placebo on Risk of Depression or Clinically Relevant Depressive Symptoms and on Change in Mood Scores: A Randomized Clinical Trial – JAMA (link to abstract – $ for full-text)
RCT: Low-cost, easy to take antiretroviral treatment based on Dolutegravir as first- or second-Line therapy found to be non-inferior to standard care for treating HIV-1 infection in children.
8 Jan, 2022 | 23:07h | UTCDolutegravir as First- or Second-Line Treatment for HIV-1 Infection in Children – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary: Easy-to-take medicine better at suppressing HIV in children – University College London
Commentaries on Twitter
Dolutegravir-based antiretroviral therapy was compared with standard care in children and adolescents starting first- or second-line therapy for HIV type 1 infection. Dolutegravir-based ART was superior to standard-care ART. https://t.co/PP0XaEVswO pic.twitter.com/pQvhjdXcUk
— NEJM (@NEJM) December 29, 2021
Visual Abstract: Dolutegravir as First- or Second-Line HIV Treatment in Children https://t.co/2RIg9uH2V1 pic.twitter.com/mDr1Z6l6CJ
— NEJM (@NEJM) January 4, 2022
Janus kinase-targeting therapies in rheumatology: a mechanisms-based approach.
8 Jan, 2022 | 22:45h | UTCJanus kinase-targeting therapies in rheumatology: a mechanisms-based approach – Nature Reviews Rheumatology (if the link is paywalled, try this one)
RCT: Vitamin D supplementation does not improve outcomes in people with early psychosis.
8 Jan, 2022 | 22:52h | UTC
5 things we learned about journal peer review in 2021.
8 Jan, 2022 | 22:51h | UTC5 Things We Learned About Journal Peer Review in 2021 – Absolutely Maybe Blog, by Hilda Bastian
Related:
A billion-dollar donation: estimating the cost of researchers’ time spent on peer review.
The $450 question: Should journals pay peer reviewers?
Opinion: Peer reviewers—time for mass rebellion?
5 things we learned about peer review in 2020
Editorial: Evaluation and Peer Review During a Pandemic
Review: Large-vessel vasculitis.
8 Jan, 2022 | 22:50h | UTCLarge-vessel vasculitis – Nature Reviews Disease Primers (if the link is paywalled, try this one)
Infographic: Large-vessel vasculitis (if the link is paywalled, try this one)
M-A of two randomized trials: Among men with high-risk non-metastatic prostate cancer, adding abiraterone and prednisolone to standard androgen-deprivation therapy was associated with improved 6-year metastasis-free survival (82% vs. 69% in the control group).
8 Jan, 2022 | 22:42h | UTCAbiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol – The Lancet (link to abstract – $ for full-text)
Related Audio: Key messages of the recent report from the STAMPEDE trial platform
Systematic Review: Active surveillance for clinically localized prostate cancer to develop recommendations regarding inclusion of intermediate-risk disease, biopsy characteristics at inclusion and monitoring, and surveillance repeat biopsy strategy.
8 Jan, 2022 | 22:41h | UTC
Commentary on Twitter
Systematic Review of AS for Clinically Localised PCa to Develop Recommendations Regarding Inclusion of Intermediate-risk Disease, Biopsy Characteristics at Inclusion and Monitoring, and Surveillance Repeat Biopsy Strategyhttps://t.co/U9mA5KqStX@Dr_Willemse @thomas_b_lam pic.twitter.com/j6dgTaqaZs
— European Urology (@EUplatinum) January 3, 2022
Meta-analysis (mostly of observational studies): In patients undergoing pancreaticoduodenectomy, routine nasogastric decompression is associated with increased rates of delayed gastric emptying, major complications, and longer length of stay compared to no routine nasogastric decompression.
8 Jan, 2022 | 22:44h | UTCRelated Study: Nasogastric Decompression vs No Decompression After Pancreaticoduodenectomy: The Randomized Clinical IPOD Trial – JAMA Surgery
Commentary on Twitter
Nasogastric decompression after pancreaticoduodenectomy 🐘 what is your practice?!
👎 Routine NG tube associated with ⬆️ rates of DGE, major complications and longer length of stay
✅ @ErasSociety policies should be standard
New meta analys on @BjsOpen https://t.co/OStyWOfrPV pic.twitter.com/tuwjPYFWia
— Giovanni Marchegiani (@Gio_Marchegiani) January 3, 2022
In a large retrospective cohort study of patients with atrial fibrillation 65 years or older, treatment with rivaroxaban compared with apixaban was associated with increased risk of major ischemic or hemorrhagic events.
8 Jan, 2022 | 22:37h | UTCCommentary: Apixaban Appears Safer, More Effective Than Rivaroxaban in Medicare Study – TCTMD
Related:
RCT: Postoperative radiotherapy (PORT) did not increase disease-free survival compared with no PORT in patients with completely resected non-small-cell lung cancer and proven mediastinal N2 involvement.
8 Jan, 2022 | 22:38h | UTCPostoperative radiotherapy versus no postoperative radiotherapy in patients with completely resected non-small-cell lung cancer and proven mediastinal N2 involvement (Lung ART): an open-label, randomised, phase 3 trial – The Lancet Oncology (link to abstract – $ for full-text)
Commentaries:
Post-Operative Radiotherapy Not Tied to Better Disease-Free Survival in NSCLC – MedPage Today (free registration required)
AAP Interim guidance on supporting the emotional and behavioral health needs of children, adolescents, and families during the COVID-19 pandemic.
17 Dec, 2021 | 09:57h | UTCCommentary: AAP Issues Guidance for Children’s Emotional Needs During COVID-19 – HealthDay
Retrospective cohort study: In patients with venous thromboembolism (VTE), treatment with apixaban was associated with lower rates for recurrent VTE and bleeding compared to rivaroxaban.
8 Jan, 2022 | 22:36h | UTCCommentaries:
Apixaban shows superior effectiveness, safety compared to rivaroxaban – ACP Internist
Recurrent VTE and Bleeding With Apixaban vs. Rivaroxaban – American College of Cardiology
RCT: Among patients hospitalized with COVID-19 at increased risk for venous thromboembolism, post-discharge thromboprophylaxis with Rivaroxaban for 35 days may improve outcomes.
17 Dec, 2021 | 09:50h | UTCInvited commentary: Anticoagulation in COVID-19 – The Lancet
Commentary on Twitter
NEW: The role of extended thromboprophylaxis in patients hospitalised with COVID-19 at risk for thrombotic events after discharge – findings from MICHELLE trial https://t.co/OWcmjCLBTw pic.twitter.com/3Bl4lV16Va
— The Lancet (@TheLancet) December 16, 2021
RCT: Molnupiravir reduced the risk of hospitalization or death in at-risk (i.e., obesity, over 60 years, etc.) unvaccinated adults with Covid-19.
17 Dec, 2021 | 09:52h | UTCRelated: Merck’s COVID pill loses its lustre: what that means for the pandemic – Nature (several articles on the subject)
WHO issues interim recommendations for heterologous COVID-19 vaccine schedules.
17 Dec, 2021 | 10:01h | UTCInterim recommendations for heterologous COVID-19 vaccine schedules – World Health Organization
Commentary: Coronavirus: WHO gives the nod for mix-and-match vaccine schedules – South China Morning Post
Randomized trial with nearly 30.000 individuals showed Novavax vaccine was safe and had an overall efficacy of 90.4% against symptomatic infections.
17 Dec, 2021 | 09:54h | UTCCommentaries:
Novavax COVID vaccine shows 90.4% efficacy against infection – CIDRAP
Novavax COVID-19 vaccine found to be safe and effective – University of Maryland School of Medicine
Related: [Preprint] In RCT with 29,949 participants, the Novavax vaccine demonstrated high overall efficacy (>90%) for the prevention of Covid-19, and all moderate-to-severe cases occurred in placebo recipients. (several articles on the subject)
CDC advisors recommend mRNA COVID vaccines over J&J.
17 Dec, 2021 | 09:46h | UTCCDC advisors recommend mRNA COVID vaccines over J&J – CIDRAP


